Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal & Cancer Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor with high specificity for ROCK1 (IC50: ~140 nM) and ROCK2 (Ki: ~300 nM), showing >200-fold selectivity against other kinases (product dossier). It disrupts Rho-mediated actomyosin contractility and stress fiber formation, modulating cell cycle and cytokinesis (Hinnant et al., 2024). Y-27632 enhances stem cell viability, reduces tumor invasion in mouse models, and is highly soluble in DMSO, ethanol, and water under defined conditions. Its actions enable precise studies of cytoskeletal dynamics, proliferation, and epithelial compartment regulation in vitro and in vivo (related ISC niche review).

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases that mediate RhoA GTPase signaling, controlling actomyosin contractility, cell morphology, and tissue architecture. In epithelial tissues such as the murine small intestine, actomyosin contractility governs cell shape, proliferation, and compartmental homeostasis (Hinnant et al., 2024). Excessive contractility in proliferative crypt cells leads to DNA damage and apoptosis, while contractility in villar cells induces non-cell autonomous crypt proliferation. Modulation of contractility is thus essential for dissecting compartment-specific responses in tissue models. Y-27632 dihydrochloride, a selective ROCK inhibitor, enables mechanistic dissection of Rho/ROCK-driven cytoskeletal dynamics and their impact on cell fate decisions.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride selectively inhibits the catalytic domains of ROCK1 and ROCK2. It binds with an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 (ApexBio). This interaction disrupts phosphorylation of downstream targets such as myosin light chain (MLC), leading to reduced actomyosin contractility and dissolution of stress fibers. Y-27632 does not substantially inhibit related kinases, including PKC, cAMP-dependent protein kinase, MLCK, or PAK, at concentrations selective for ROCK inhibition (selectivity >200-fold). Inhibition of ROCK signaling impairs cytokinesis and blocks cell cycle progression from G1 to S phase in some cell types.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of ~140 nM and ROCK2 with a Ki of ~300 nM, showing >200-fold selectivity against unrelated kinases (ApexBio).
• Application to murine intestinal crypts demonstrates that ROCK inhibition reduces DNA damage and apoptosis caused by contractility, highlighting compartment-specific cytoprotective effects (Hinnant et al., 2024).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (≥1 µM), modulating cell cycle progression (ApexBio).
• In vivo, Y-27632 administration reduces tumor invasion and metastasis in mouse models of cancer (ApexBio).
• Stock solutions are stable at -20°C for several months; solubility is ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is broadly used in cytoskeletal research, stem cell maintenance, cancer invasion models, and studies of epithelial compartmentalization. In intestinal and neuroepithelial models, it clarifies the relationship between actomyosin contractility, proliferation, and tissue homeostasis (see neuro-epithelial modeling). Compared to earlier reviews (precision inhibition in neuroepigenetics), this article integrates recent findings on compartment-specific responses and benchmarks achievable selectivity/solubility profiles.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all Rho pathway kinases; selectivity is restricted to ROCK1/2 at recommended concentrations.
• It does not promote proliferation in all contexts; in some systems, it blocks cell cycle progression or induces apoptosis.
• Y-27632 is not suitable for long-term storage as a solution above -20°C; degradation may occur.
• It does not substitute for genetic knockdown of ROCK, as off-target effects may arise at supra-physiological concentrations.
• Solubility in aqueous buffer may require warming or sonication; precipitation limits effective working concentrations in some protocols.

Workflow Integration & Parameters

For in vitro use, dissolve Y-27632 dihydrochloride at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Warm to 37°C or use an ultrasonic bath if precipitation occurs. Stock solutions are stable below -20°C for several months; avoid repeated freeze-thaw cycles. Typical working concentrations range from 1–50 µM, depending on cell type and assay. Solid material should be stored desiccated at 4°C or below. For cancer and stem cell research, titrate dose to minimize off-target effects. In mouse models, follow published protocols for dosing and route of administration (ApexBio). For integration in human or organoid intestinal stem cell workflows, consult recent advances (human ISC aging/regeneration), extending basic cytoskeletal studies to translational models.

Conclusion & Outlook

Y-27632 dihydrochloride remains the benchmark selective ROCK inhibitor for dissecting Rho/ROCK signaling, cytoskeletal organization, and epithelial compartment dynamics. Its use in research continues to clarify how contractility governs cell fate, proliferation, and tissue integrity. Ongoing studies leverage its selectivity and solubility to enable precision manipulation of cytoskeletal signaling in both basic and translational models. For further information or to purchase, see the A3008 kit.